Thank you to our speakers, sponsors, and delegates who joined us in December 2023 for the summit! Register your interest to be the first to hear updates about the 2024 meeting.
Join Your Peers at the Next Meeting in the TRP Series:
Attending Companies Included:
Advancing Next Generation Radioligand Candidates to Commercialisation Through Rigorous Clinical Rationale, Novel Target Selection & Reliable Supply Chain Design
Ushering In the New Age of Targeted Radiopharmaceuticals
There has been so much progress in the TRP field recently with Novartis’s Lutathera hitting the primary endpoint in a Phase III trial, Genentech partnering up with PeptiDream to enter the radiopharma space, Eli Lilly’s billion-dollar deal to buy Point Biopharma and so much more!
The Targeted Radiopharmaceuticals Summit returned for its 5th year, bringing to you never seen before speakers from the likes of Novartis, Bayer, AstraZeneca, Bicycle Therapeutics and more, all of whom delved into all of our audience's challenges whether its related to discovering novel targets to transform your TRP development, working with low isotope availability to ensure tight manufacturing timelines are met, selecting the right target molecule to increase tumour targeting accuracy, answering regulatory questions, transitioning molecule through the clinic or understanding the investor landscape.
Our audience attended this conference to master the complexity of TRPs by meeting the specific needs of the patient and taking TRPs to the front line of cancer treatment to make a difference.